Northwest Biotherapeutics, Inc. (NWBO)
OQB · Healthcare · Biotechnology
$0.20
+5.26%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$328.7M
Shares Outstanding
1.64B
P/S (TTM)
220x
Exchange
OQB
Currency
USD
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 131K | 200K | 672K | 494K |
| Operating Income | -14.8M | -14.3M | -13.5M | -10.9M |
| Net Income | -15.4M | -26.8M | 1.4M | -3.1M |
| Diluted EPS | $-0.01 | $-0.02 | $nan | $0.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating Income | -67.2M | -55.5M | -66.5M | -59.9M |
| Net Income | -105.0M | -62.6M | -83.8M | -60.2M |
| Diluted EPS | $-0.10 | $-0.06 | $-0.07 | $-0.04 |